Metastatic Solid Tumor
119
47
67
12
Key Insights
Highlights
Success Rate
39% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
16.0%
19 terminated out of 119 trials
38.7%
-47.8% vs benchmark
0%
0 trials in Phase 3/4
83%
10 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (119)
Study of LP-184 in Patients With Advanced Solid Tumors
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Study of ZE94-0605 in Patients With Advanced Solid Tumors, With Dose Expansion Cohorts.
Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors